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Abstract: The aim of this study was to identify new compounds active against 
Plasmodium falciparum based on our previous research carried out on 3-phenyl-
quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives. Twelve compounds were 
synthesized and evaluated for antimalarial activity. Eight of them showed an IC50 < 1 μM 
against the 3D7 strain. Derivative 1 demonstrated high potency (IC50= 0.63 µM) and good 
selectivity (SI=10.35), thereby becoming a new lead-compound. 
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Introduction 
 
Malaria is by far the world’s most important tropical parasitic disease. Mortality, currently 
estimated at over a million people per year, has risen in recent years, probably due to increasing 
resistance to antimalarial medicines. It exacts a heavy toll of illness and death - especially amongst 
children and pregnant women. It also poses a risk to travellers and immigrants, with imported cases 
increasing in non-endemic areas [1]. A major drawback in the chemotherapy of malaria is the rapid 
and widespread development of drug resistance in Plasmodia to most existing antimalarials [2, 3]. 
This is the reason research was aimed at the development of new antimalarials [4]. 
Based on activity results, our group had previously synthesized 3-phenylquinoxaline-2-carbonitrile 
1,4-di-N-oxide derivatives [5], and in attempts to establish the structural requirements for inhibition of 
P. falciparum, we decided to synthesize new compound series with a structural modifications from our 
previous lead-compounds (Figure 1). The change that was carried out was the substitution of the 
phenyl subunit in position 3 by 2-furyl (series A) or 2-thienyl (series B) moieties, following the 
classical notion of bioisosteric replacement used in Medicinal Chemistry [6], in order to determine the 
influence of the size and nature of aromatics rings in this position.  
 
Figure 1. Design of new derivatives as antimalarial drugs from our previous lead. 
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Results and Discussion 
 
The most potent quinoxaline derivative from our previous in vitro studies was 3-(4’-chloro-
phenyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide [5] which was subjected to a structural change in 
order to obtain new active compounds: replacement of the benzene in position 3 of the quinoxaline 
subunit by a heteroaromatic 5-membered 2-furan or 2-thiophene ring. 
Twelve new compounds were thus synthesized and evaluated for antimalarial activity against 
Plasmodium falciparum. The modified quinoxaline 1,4-di-N-oxide derivatives 1-12 were evaluated 
against the CQ (chloroquine)-sensitive 3D7 strain and the results are listed in Table 1. Compounds 
were selected for further assays if their IC50 values were less than 1 μM when tested against said 3D7 
strain. The chosen compounds were then tested against K1 strain (CQ-resistant) and their 
cytotoxicities were determined in mammalian KB cells (Table 1). 
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Upon carrying out the biosteric replacement of phenyl subunit with a heteroaromatic 5-membered 
ring, the importance of the heteroatom is clearly observed; only two of the 2-thienyl derivatives (series 
B) showed an IC50 <1 μM, whereas all of the 2-furyl derivatives (series A) show IC50 values ranging 
from 0.49 to 0.93 μM. 
All of the derivatives that were tested showed superior activity towards the K1 strain, in 
comparison with chloroquine (IC50(1-6)<IC50(CQ)). In this way, the 3-(2’-furyl)quinoxaline-2-
carbonitrile 1,4-di-N-oxide derivatives appear to be novel and promising antimalarial candidates. 
The activities of these derivatives are also affected by the different substituents on the quinoxaline 
nucleus: regarding the R7 position, it has been observed that the presence of a trifluoromethyl (5, 11) 
or a methoxy (6, 12) group results in two of the most potent compounds in each series. The 7-chloro 
derivatives 3, 9 show contrasted effects: while the furyl derivative 3 is the most potent compound 
against 3D7 and the second most active against K1, the thienyl derivative 9 was inactive towards 3D7.  
Unfortunately, the most active compounds against P. falciparum (3, 5 and 6 in series A and 11 and 
12 in series B) are also cytotoxic in KB cells, with IC50 values lower than 4 µM. The most cytotoxic 
derivatives are 5, 11, which include a CF3 group in position R7 of the quinoxaline ring, and the least 
cytotoxic compound is the 3-furyl derivative 1 nonsubstituted in the R7 position. 
 
Table 1. Structures, in vitro activity against P. falciparum (3D7 and K1 strains) and 
cytotoxicity in mammalian KB cells. 
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N
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Comp. R7 X 
3D7 IC50 
(µM)a 
K1 IC50 
(µM)a 
KB IC50 
(μM)a 
1 H O 0.75±0.31 0.63±0.18 6.52±0.86 
2 F O 0.77±0.22 0.59±0.06 5.59±0.44 
3 Cl O 0.49±0.28 0.34±0.04 3.48±0.78 
4 CH3 O 0.93±0.41 0.56±0.01 4.38±0.50 
5 CF3 O 0.53±0.25 0.37±0.12 3.00±0.43 
6 OCH3 O 0.63±0.14 0.28±0.07 3.17±0.67 
7 H S 2.97±0.33 NDb ND 
8 F S >10 ND ND 
9 Cl S 7.41±0.20 ND ND 
10 CH3 S 2.86±0.46 ND ND 
11 CF3 S 0.89±0.36 ND 1.80±0.47 
12 OCH3 S 0.80±0.10 ND 3.80±0.22 
CQc   0.0135 0.682 110 
a  Figures are the mean IC50 values (μM) ± standard derivation from independent 
experiments each performed in triplicate. 
b  No data 
c  Chloroquine is used as a standard drug. 
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As observed in Table 1, all of the 3-furyl derivatives showed a tendency towards lower IC50 values 
against the K1 strain than against the 3D7 one. The most interesting results were obtained from 
calculating the Resistance and Selectivity Indexes (RI and SI) of selected compounds (IC50 < 1 µM), 
as illustrated in Table 2. While chloroquine shows an IC50 50 times higher in the K1 strain than in the 
3D7 strain (RI = 50), we obtained RI values lower than 1 for all of our most active compounds (Table 
2). This fact suggests low levels of cross-resistance to CQ [7]. 
 
Table 2. Resistance index (RI) and Selectivity indexes (SI). 
Comp. RIa (K1/3D7) SIb 3D7 SIb K1 
1 0.84 8.69 10.35 
2 0.76 7.26 9.47 
3 0.69 7.10 10.24 
4 0.60 4.81 7.82 
5 0.71 5.66 8.11 
6 0.44 5.03 11.32 
CQc 50.52 8150 161 
a Resistance Index. calculated as (3D7 IC50)/(K1 IC50). 
b Selectivity Index calculated as (KB IC50)/(P. falciparum IC50). 
c Chloroquine is used as a standard drug. 
 
With regard to the selectivity of the compounds, the SI value required for a compound to be 
selected for in vivo assays is 10 [8]. Four of the tested derivatives (1, 2, 3 and 6) showed a SI value 
close to the established cut-off with respect to the K1 strain; in addition, the 3-(2’-furyl) derivative 1, 
nonsubstituted in the R7 position, was the most selective compound with respect to the 3D7 strain. The 
potency, low cytotoxicity and selectivity of 3-(2’-furyl)quinoxaline 1,4-di-N-oxide (1) make it valid 
lead for synthesizing new compounds that may possess better activity. 
 
Conclusions 
 
Screening of the in vitro antimalarial activity of these novel series has evidenced that the 3-(2’-
furyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives 1-6 appear to be novel and promising 
antimalarial candidates, improving upon the activity of chloroquine against the K1 strain. The 
nonsubstituted derivative in position R7 is especially noteworthy, as it showed the lowest cytotoxicity 
and the highest SI values. 
 
Experimental  
 
General 
 
All of the synthesized compounds were chemically characterized by thin layer chromatography 
(TLC), infrared (IR), nuclear magnetic resonance (1H-NMR), mass spectra (MS) and elemental 
microanalysis (CHN). Alugram SIL G/UV254 (Layer: 0.2 mm) (Macherey-Nagel GmbH & Co. KG. 
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Postfach 101352. D-52313 Düren, Germany) was used for Thin Layer Chromatography and Silica gel 
60 (0.040-0.063 mm) for Column flash Chromatography (Merck). The 1H-NMR spectra were recorded 
on a Bruker 400 Ultrashield instrument (400 MHz), using TMS as the internal standard and with 
CDCl3 as the solvent; the chemical shifts are reported in ppm (δ) and coupling constants (J) values are 
given in Hertz (Hz). Signal multiplicities are represented by: s (singlet), d (doublet), t (triplet), q 
(quadruplet), dd (double doublet) and m (multiplet). The IR spectra were performed on a Thermo 
Nicolet Nexus FTIR (Madison, USA) in KBr pellets; the frequencies are expressed in cm-1. The mass 
spectra were measured on an Agilent Technologies Model MSD/DS 5973N (mod. G2577A) mass 
spectrometer with direct insertion probe (DIP) (Waldbronn, Germany) and the ionization method was 
electron impact (EI, 70 eV). Elemental microanalyses were obtained on an Elemental Analyzer (Leco 
CHN-900, Tres Cantos, Madrid, Spain) from vacuum-dried samples. The analytical results for C, H, 
and N, were within ± 0.4 of the theoretical values. Chemicals were purchased from Panreac Química 
S.A. (Montcada i Reixac, Barcelona, Spain), Sigma-Aldrich Química, S.A., (Alcobendas, Madrid), 
Acros Organics (Janssen Pharmaceuticalaan 3a, 2440 Geel, Belgium) and Lancaster (Bischheim-
Strasbourg, France). 
 
Synthesis of 3-(2’furyl) and 3-(2’-thienyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives 1-12 
 
The required 3-arylquinoxaline-2-carbonitrile derivatives were obtained by the classical Beirut 
reaction [9]. The method used for their synthesis has been reported previously [5, 10]. The appropriate 
benzofuroxan and the corresponding arylacetonitrile were dissolved in dry dichloromethane in the 
presence of triethylamine, which acted as the catalyst.  
 
3-(2’-Furyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide (1). IR υ/cm-1: 2233, 1336; 1H-NMR δ/ppm: 
6.80 (td, J=1.77, 3.65 Hz, 1H, H4’), 7.86 (d, J=0.74 Hz, 1H, H3’), 7.91 (tdd, J=1.40, 7.13, 8.61 Hz, 1H, 
H7), 8.01 (tdd, J=1.52, 7.11, 8.63 Hz, 1H, H6), 8.38 (dd, J=0.90, 3.64 Hz, 1H, H5’), 8.62 (d, J=8.58 Hz, 
1H, H8), 8.70 (d, J=8.64 Hz, 1H, H5); Anal. calcd. for C13H7N3O3 (253.22): C, 61.66; H, 2.79; N, 
16.59. Found: C, 61.67; H, 2.86; N, 16.92; MS m/z (%): 253 ([M·]+, 51), 237 (25), 191 (52), 175 (36), 
105 (100). 
 
7-Fluoro-3-(2’-furyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide (2). IR υ/cm-1: 2238, 1327; 1H-NMR 
δ/ppm: 6.81 (td, J=1.75, 3.70 Hz, 1H, H4’), 7.73 (ddd, J=2.77, 7.26, 9.96 Hz, 1H, H6), 7.87 (dd, 
J=0.73, 1.69 Hz, 1H, H3’), 8.28 (dd, J=2.69, 7.97 Hz, 1H, H8), 8.35 (dd, J=0.71, 3.66 Hz, 1H, H5’), 
8.73 (dd, J=4.94, 9.45 Hz, 1H, H5); Anal. calcd. for C13H6FN3O3 (271.21): C, 57.57; H, 2.23; N, 15.49. 
Found: C, 57.77; H, 2.21; N, 15.87. 
 
7-Chloro-3-(2’-furyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide (3). IR  υ/cm-1: 2226, 1323; 1H-NMR 
δ/ppm: 6.81 (td, J=1.78, 3.66 Hz, 1H, H4’), 7.87 (dd, J=0.77, 1.69 Hz, 1H, H3’), 7.92 (dd, J= 2.21, 9.18 
Hz, 1H, H6), 8.37 (dd, J=0.75, 3.66 Hz, 1H, H5’), 8.60 (dd, J=0.45, 2.20 Hz, 1H, H8), 8.64 (d, J=9.18 
Hz, 1H, H5); Anal. calcd. for C13H6ClN3O3 (287.66): C, 54.28; H, 2.10; N, 14.61. Found: C, 54.30; H, 
2.29; N, 14.74; MS m/z (%): 287 ([M·]+, 100), 271 (30). 
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7-Methyl-3-(2’-furyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide (4). IR υ/cm-1: 2226, 1330; 1H-NMR  
δ/ppm: 2.67 (s, 3H, C7’-CH3), 6.79 (td, J=0.60, 2.57 Hz, 1H, H4’), 7.81 (dd, J=1.82, 8.81 Hz, 1H, H6), 
7.87 (dd, J=0.78, 1.72 Hz, 1H, H3’), 8.34 (dd, J=0.72, 3.63 Hz, 1H, H5’), 8.40 (s, 1H, H8), 8.58 (d, 
J=8.80 Hz, 1H, H5); Anal. calcd. for C14H9N3O3 (267.25): C, 62.92; H, 3.39; N, 15.72. Found: C, 
62.54; H, 3.48; N, 15.77; MS m/z (%): 267 ([M·]+, 100), 251 (21). 
 
7-Trifluoromethyl-3-(2’-furyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide (5). IR υ/cm-1: 2232, 1342, 
1318; 1H-NMR δ/ppm: 6.83 (td, J=1.67, 3.65 Hz, 1H, H4’), 7.90 (dd, J=0.73, 1.57 Hz, 1H, H3’), 8.17 
(dd, J=1.65, 8.88 Hz, 1H, H6), 8.45 (dd, J=0.77, 3.69 Hz, 1H, H5’), 8.83 (d, J=8.99 Hz, 1H, H5), 8.91 
(s, 1H, H8); Anal. calcd. for C14H6F3N3O3 (321.22): C, 52.35; H, 1.88; N, 13.08. Found: C, 52.53; H, 
1.90; N, 12.90. 
 
7-Methoxy-3-(2’-furyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide (6). IR υ/cm-1: 2226, 1329; 1H-NMR 
δ/ppm: 4.06 (s, 3H, C7’-OCH3), 6.77 (td, J=1.75, 3.63 Hz, 1H, H4’), 7.57 (dd, J=2.74, 9.52 Hz, 1H, H6), 
7.83 (dd, J=0.68, 1.67 Hz, 1H, H3’), 8.28 (dd, J=0.58, 3.62 Hz, 1H, H5’), 7.89 (d, J=2.66, 1H, H8), 8.59 
(d, J=9.50 Hz, 1H, H5); Anal. calcd. for C14H9N3O4 (283.25): C, 59.37; H, 3.20; N, 14.84. Found: C, 
59.14; H, 3.27; N, 15.00; MS m/z (%): 283 ([M·]+, 100), 267 (26). 
 
3-(2’-Thienyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide (7). IR υ/cm-1: 2225, 1352, 1322; 1H-NMR 
δ/ppm: 7.38 (td, J=4.29, 5.10 Hz, 1H, H4’), 7.87 (dd, J=0.96, 5.12 Hz, 1H, H3’), 7.92 (ddd, J=1.28, 
7.10, 8.48 Hz, 1H, H7), 8.03 (ddd, J=1.37, 7.11, 8.60 Hz, 1H, H6), 8.61 (dd, J=1.32, 8.59 Hz, 1H, H8), 
8.69 (dd, J=0.96, 4.26 Hz, 1H, H5’), 8.74 (dd, J=1.22, 8.63 Hz, 1H, H5); Anal. calcd. for C13H7N3O2S 
(269.28): C, 57.99; H, 2.62; N, 15.60. Found: C, 57.72; H, 2.63; N, 15.75; MS m/z (%): 269 ([M·]+, 
100), 253 (43), 224 (54). 
 
7-Fluoro-3-(2’-thienyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide (8). IR υ/cm-1: 2219, 1354, 1312; 1H-
NMR δ/ppm: 7.39 (td, J=4.74, 5.10 Hz, 1H, H4’), 7.76 (ddd, J=2.74, 7.26, 9.91 Hz, 1H, H6), 7.89 (dd, 
J=0.89, 5.12 Hz, 1H, H3’), 8.27 (dd, J=2.23, 7.90 Hz, 1H, H8), 8.66 (dd, J=0.80, 4.30 Hz, 1H, H5’), 
8.77 (dd, J=4.92, 9.50 Hz, 1H, H5); Anal. calcd. for C13H6FN3O2S (287.27): C, 54.35; H, 2.11; N, 
14.63. Found: C, 54.59; H, 2.14; N, 15.00. 
 
7-Chloro-3-(2’-thienyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide (9). IR υ/cm-1: 2228, 1353, 1311; 
1H-NMR δ/ppm: 7.39 (m, 1H, H4’), 7.89 (dd, J=1.00, 5.51 Hz, 1H, H3’), 7.94 (dd, J= 2.23, 9.21 Hz, 
1H, H6), 8.59 (d, J=2.21 Hz, 1H, H8), 8.68 (d, J=9.17 Hz, 1H, H5), 8.69 (dd, J=0.98, 4.27 Hz, 1H, H5’); 
Anal. calcd. for C13H6ClN3O2S (303.73): C, 51.41; H, 1.99; N, 13.83. Found: C, 51.26; H, 2.08; N, 
14.14; MS m/z (%): 303 ([M·]+, 99), 287 (53), 273 (45), 258 (100). 
 
7-Methyl-3-(2’-thienyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide (10). IR υ/cm-1: 2232, 1343, 1318; 
1H-NMR δ/ppm: 2.67 (s, 3H, C7’-CH3), 7.37 (td, J=4.34, 5.04 Hz, 1H, H4’), 7.83 (dd, J=1.43, 8.72 Hz, 
1H, H6), 7.86 (dd, J=0.87, 4.25 Hz, 1H, H3’), 8.39 (s, 1H, H8), 8.61 (d, J=8.81 Hz, 1H, H5), 8.66 (dd, 
J=0.90, 4.24 Hz, 1H, H5’); Anal. calcd. for C14H9N3O2S (283.31): C, 59.35; H, 3.20; N, 14.83. Found: 
C, 59.32; H, 3.16; N, 14.52; MS m/z (%): 283 ([M·]+, 100), 267 (41), 238 (54). 
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7-Trifluoromethyl-3-(2’-thienyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide (11). IR υ/cm-1: 2230, 1354, 
1314; 1H-NMR δ/ppm: 7.42 (td, J=4.32, 5.16 Hz, 1H, H4’), 7.93 (dd, J=0.95, 5.09 Hz, 1H, H3’), 8.20 
(dd, J=1.83, 9.03 Hz, 1H, H6), 8.76 (dd, J=0.93, 4.28 Hz, 1H, H5’), 8.87 (d, J=8.97 Hz, 1H, H5), 8.90 
(s, 1H, H8); Anal. calcd. for C14H6F3N3O2S (337.28): C, 49.86; H, 1.79; N, 12.46. Found: C, 50.04; H, 
1.84; N, 12.82. 
 
7-Methoxy-3-(2’-thienyl)quinoxaline-2-carbonitrile 1,4-di-N-oxide (12). IR υ/cm-1: 2231, 1351, 1313; 
1H-NMR δ/ppm: 4.07 (s, 3H, C7’-OCH3), 7.35 (td, J=4.23, 5.14 Hz, 1H, H4’), 7.59 (dd, J=2.75, 9.50 
Hz, 1H, H6), 7.83 (dd, J=1.03, 5.13 Hz, 1H, H3’), 7.88 (d, J=2.64, 1H, H8), 8.60 (dd, J=1.01, 4.23 Hz, 
1H, H5’), 8.63 (d, J=9.52 Hz, 1H, H5); Anal. calcd. for C14H9N3O3S (299.31): C, 56.18; H, 3.03; N, 
14.04. Found: C, 56.08; H, 3.27; N, 14.19; MS m/z (%): 299 ([M·]+, 26), 285 (63), 256 (24), 167 (39), 
111 (100). 
 
Plasmodium falciparum in vitro culture and parasite growth inhibition assays 
 
In vitro evaluation of the antimalarial activity was carried out at the London School of Hygiene 
and Tropical Medicine. Biological tests were performed according to the previously described method 
[11]. All parasite clones, isolates and strains were acquired from MR4 (Malaria Research and 
Reference Reagent Resource Center, Manassas, Virginia, USA). Strains/isolates used in this study 
were: the drug sensitive 3D7 clone of the NF54 isolate (unknown origin); and the chloroquine, 
pyrimethamine and cycloguanyl resistant K1 strain (Thailand). In vitro culture of P. falciparum was 
carried out following standard methods [12] with modifications as described [8]. In vitro parasite 
growth inhibition was assessed by the incorporation of [3H] hypoxanthine based on the method used 
by Desjardins [13] and modified as described [11]. Briefly, stock drug solutions were dissolved in 
100% dimethylsulfoxide (Sigma, Dorset, UK) and 50 μL of a 3-fold dilution series (10.0, 3.33, 1.11, 
0.370, 0.124, and 0.0412 μg/mL) of the drugs prepared in assay medium [RPMI 1640 supplemented 
with 0.5% Albumax II (Invitrogen), 0.2% w/v glucose, 0.03% L-glutamine, and 5 μM hypoxanthine] 
added to each well of 96-well plates in triplicate. Fifty microlitres of asynchronous (65–75% ring 
stage) P. falciparum culture (0.5% parasitemia) or uninfected erythrocytes (blank) were added to each 
well reaching a final volume of 100 μL per well, a final hematocrit of 2.5% and final 
dimethylsulfoxide concentrations ≤0.01%. Plates were incubated at 37 °C in 5% CO2, and 95% air 
mixture for 24 h, at which point [3H]hypoxanthine (Perkin-Elmer, Hounslow, UK, 10 μL) was added 
to each well (0.2 μCi/well). After an additional 24 h incubation period, the experiment was terminated 
by placing the plates in a -80 °C freezer. Plates were thawed and harvested onto glass fibre filter mats 
using a 96-well cell harvester (Harvester 96, Tomtec, Oxon, UK) and left to dry. After the addition of 
MeltiLex solid scintillant (Perkin–Elmer, Hounslow, UK) the incorporated radioactivity was counted 
using a Wallac 1450 Betalux scintillation counter (Wallac). Data acquired by the Wallac BetaLux 
scintillation counter were exported into a MICROSOFT EXCEL spreadsheet (Microsoft), and the IC50 
values of each drug were calculated by using XLFit line fitting software (ID Business Solutions, UK). 
Chloroquine diphosphate, as a standard drug, and control wells with untreated infected and uninfected 
erythrocytes were included in all assays. Generally, compounds showing a IC50 value greater than 2 
μM in 3D7 strain are not further evaluated. 
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In vitro cytotoxicity assay 
 
Concurrent with the determination of IC50 in K1 strain, compounds were tested for cytotoxicity 
(IC50) in KB cells at concentrations less than or equal to 100 µg/mL. After 72 hours of exposure, 
viability is assessed on the basis of the Alamar Blue method (Accumed International, USA) as 
previously described [8, 11]. Briefly, microtiter plates were seeded at a density of 4·104 KB cells/mL 
in RPMI 1640 culture medium supplemented with 10% heat-inactivated foetal calf serum (complete 
medium, Seralab). Plates were incubated at 37°C, 5% CO2, 95% air mixture for 24 h followed by 
compound addition to triplicate wells in a dilution series in complete medium. The positive control 
drug was podophyllotoxin (Sigma). Plates were incubated for a further 72 h followed by the addition 
of 10 μL of Alamar-Blue (AccuMed International) to each well and incubation for 2–4 h at 37 °C, 5% 
CO2, 95% air mixture. Fluorescence emission at 585 nm was measured in a Spectramax Gemini plate 
reader (Molecular Devices) after excitation at 530 nm. IC50 values were calculated using the XLFit (ID 
Business Solutions, UK) line fitting software. The Selectivity Index [(SI=(KB IC50)/(3D7 or K1 IC50)] 
was also determined; it is considered significant when SI >10. 
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